Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.
On March 7, it is poised to become the first drug maker to place a condition on 340B sales and deliveries to covered entity in-house pharmacies. Until now, drug manufacturer conditions and the lawsuits they have spawned have focused on 340B sales and deliveries to contract pharmacies.
Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
